Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 May;13(5):258-9.
doi: 10.1038/nrgastro.2016.52. Epub 2016 Mar 23.

Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand?

Marta Schirripa  1 , Heinz-Josef Lenz  1
Affiliations
Comment

Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand?

Marta Schirripa et al. Nat Rev Gastroenterol Hepatol. 2016 May.

Abstract

In the past few years, the mechanisms leading to an acquired resistance to anti-EGFR monoclonal antibodies became an important topic in metastatic colorectal cancer research. In this commentary, we briefly summarize the latest update to this field by Arena and colleagues, and discuss promising new drugs and treatment strategies that might lead to overcoming secondary resistance.

PubMed Disclaimer

Comment on

References

    1. Sorich MJ et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann. Oncol. 26, 13–21 (2015). - PubMed
    1. Arena S et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin. Cancer Res. 21, 2157–2166 (2015). - PubMed
    1. Dienstmann R, Salazar R & Tabernero J Overcoming resistance to anti-EGFR therapy in colorectal cancer. Am. Soc. Clin. Oncol. Educ. Book e149–e156 (2015). - PubMed
    1. Misale S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532–536 (2012). - PMC - PubMed
    1. Kearns JD et al. Enhanced targeting of the EGFR network with MM-151, an oligoclonal anti-EGFR antibody therapeutic. Mol. Cancer Ther. 14, 1625–1636 (2015). - PubMed